AIM ImmunoTech (AIM) Competitors $2.44 -0.02 (-0.81%) Closing price 04:00 PM EasternExtended Trading$2.49 +0.05 (+2.05%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AIM vs. DARE, AKTX, TENX, TRIB, ASBP, MIRA, RNTX, ENLV, BCAB, and FBLGShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Dare Bioscience (DARE), Akari Therapeutics (AKTX), Tenax Therapeutics (TENX), Trinity Biotech (TRIB), Aspire Biopharma (ASBP), MIRA Pharmaceuticals (MIRA), Rein Therapeutics (RNTX), Enlivex Therapeutics (ENLV), BioAtla (BCAB), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Its Competitors Dare Bioscience Akari Therapeutics Tenax Therapeutics Trinity Biotech Aspire Biopharma MIRA Pharmaceuticals Rein Therapeutics Enlivex Therapeutics BioAtla FibroBiologics AIM ImmunoTech (NYSE:AIM) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Do analysts rate AIM or DARE? AIM ImmunoTech currently has a consensus target price of $275.00, indicating a potential upside of 11,170.49%. Dare Bioscience has a consensus target price of $10.00, indicating a potential upside of 369.48%. Given AIM ImmunoTech's higher possible upside, research analysts plainly believe AIM ImmunoTech is more favorable than Dare Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Dare Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of AIM or DARE? 12.0% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by insiders. Comparatively, 4.8% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, AIM or DARE? AIM ImmunoTech has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Which has stronger earnings & valuation, AIM or DARE? Dare Bioscience has lower revenue, but higher earnings than AIM ImmunoTech. Dare Bioscience is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAIM ImmunoTech$121K54.63-$28.96M-$24.68-0.10Dare Bioscience$10K2,871.24-$4.05M-$2.14-1.00 Is AIM or DARE more profitable? Dare Bioscience has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Dare Bioscience's return on equity of 0.00% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets AIM ImmunoTech-12,594.21% -421.73% -147.54% Dare Bioscience N/A N/A -103.70% Does the media refer more to AIM or DARE? In the previous week, Dare Bioscience had 1 more articles in the media than AIM ImmunoTech. MarketBeat recorded 3 mentions for Dare Bioscience and 2 mentions for AIM ImmunoTech. Dare Bioscience's average media sentiment score of 0.50 beat AIM ImmunoTech's score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AIM ImmunoTech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDare Bioscience beats AIM ImmunoTech on 11 of the 14 factors compared between the two stocks. Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$6.61M$282.63M$5.75B$21.26BDividend YieldN/AN/A6.67%3.52%P/E Ratio-5.19N/A78.4329.40Price / Sales54.63477.76546.9449.02Price / CashN/A22.4437.0524.13Price / Book12.2011.4110.914.54Net Income-$28.96M-$115.81M$3.29B$999.70M7 Day Performance-3.94%2.35%0.01%0.12%1 Month Performance-18.94%1.01%7.06%5.75%1 Year Performance-92.82%-14.14%50.09%14.88% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech0.9206 of 5 stars$2.44-0.8%$275.00+11,170.5%-92.8%$6.61M$121K-5.1920DAREDare Bioscience1.9826 of 5 stars$2.03-0.5%$12.00+491.1%-42.8%$27.36M$10K-0.9530News CoverageAnalyst UpgradeGap UpAKTXAkari Therapeutics3.3804 of 5 stars$0.85-1.6%$5.00+491.0%-82.8%$27.22MN/A0.009News CoverageShort Interest ↑Gap UpHigh Trading VolumeTENXTenax Therapeutics1.3616 of 5 stars$5.97+1.1%$17.00+185.0%+56.0%$27.22MN/A-6.489TRIBTrinity Biotech0.6673 of 5 stars$1.50+2.0%N/A-85.2%$27.08M$61.56M-0.51480Short Interest ↑ASBPAspire BiopharmaN/A$0.54+2.3%N/AN/A$26.91MN/A0.00N/ANews CoverageMIRAMIRA Pharmaceuticals3.1756 of 5 stars$1.39-0.4%$17.00+1,127.4%-22.8%$26.41MN/A-2.832Short Interest ↓RNTXRein TherapeuticsN/A$1.13-1.8%N/AN/A$26.33MN/A-0.429News CoveragePositive NewsGap UpENLVEnlivex Therapeutics3.43 of 5 stars$1.09+0.9%$10.00+817.4%-15.9%$26.02MN/A-1.6770Analyst ForecastShort Interest ↓Analyst RevisionGap UpBCABBioAtla1.5028 of 5 stars$0.45+9.7%$5.00+1,021.1%-73.3%$25.95M$11M-0.4060Gap UpHigh Trading VolumeFBLGFibroBiologics2.4518 of 5 stars$0.60-0.8%$13.00+2,066.7%-63.0%$25.13MN/A-1.6710Gap Up Related Companies and Tools Related Companies DARE Alternatives AKTX Alternatives TENX Alternatives TRIB Alternatives ASBP Alternatives MIRA Alternatives RNTX Alternatives ENLV Alternatives BCAB Alternatives FBLG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AIM) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIM Stock Alerts